Vicore Pharma publishes the Annual Report for 2021
Gothenburg, April 7, 2022 –Vicore Pharma Holding AB (publ) (“Vicore”), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2 receptor (ATRAGs), today announced the publication of the Annual Report for the financial year 2021.
The Annual Report for the financial year 2021 is available on the company’s website: https://vicorepharma.com/investors/financial-reports/
For further information, please contact:
Hans Jeppsson, CFO, tel: +46 70 553 14 65, hans.jeppsson@vicorepharma.com
This information is information that Vicore Pharma Holding AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 08:00 CET on 7 April 2022.
About Vicore Pharma Holding AB (publ)
Vicore is a clinical-stage pharmaceutical company focused on developing innovative medicines in severe lung diseases where the Angiotensin II type 2 receptor (AT2R) plays an important role. The company currently has four development programs, VP01, VP02, VP03 and VP04. VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (IPF), pulmonary artery hypertension (PAH) and COVID-19. VP02 is a new formulation and delivery route of thalidomide and focuses on the underlying disease and the severe cough associated with IPF. VP03 includes the development of new AT2 receptor agonists. VP04 develops a clinically validated digital therapeutic for IPF patients.
The company's shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see www.vicorepharma.com.